Canaccord Genuity Group Issues Pessimistic Forecast for Globus Medical (NYSE:GMED) Stock Price

Globus Medical (NYSE:GMED) had its price objective decreased by equities researchers at Canaccord Genuity Group from $115.00 to $105.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group‘s target price would suggest a potential upside of 45.55% from the company’s current price.

A number of other equities analysts also recently commented on GMED. BTIG Research restated a “neutral” rating on shares of Globus Medical in a report on Friday. Royal Bank Of Canada decreased their target price on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. Truist Financial dropped their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. Finally, UBS Group started coverage on shares of Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and an average target price of $96.46.

Globus Medical Price Performance

NYSE:GMED traded down $9.30 on Friday, reaching $72.14. The stock had a trading volume of 6,017,490 shares, compared to its average volume of 1,501,928. Globus Medical has a 12-month low of $70.74 and a 12-month high of $101.40. The company has a market cap of $9.69 billion, a price-to-earnings ratio of 18.43, a P/E/G ratio of 1.40 and a beta of 0.98. The firm’s fifty day moving average is $77.44 and its two-hundred day moving average is $83.29.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $763.72 million during the quarter, compared to the consensus estimate of $792.39 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts forecast that Globus Medical will post 4.99 earnings per share for the current fiscal year.

Insider Activity at Globus Medical

In other Globus Medical news, Director Ann D. Rhoads sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares in the company, valued at $3,007,640. This represents a 12.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James Tobin sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the sale, the director directly owned 15,000 shares of the company’s stock, valued at $1,118,700. This trade represents a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 60,000 shares of company stock worth $4,838,400. 18.38% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Elevation Wealth Partners LLC increased its stake in Globus Medical by 2,178.6% during the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after buying an additional 305 shares during the period. Continuum Advisory LLC acquired a new position in Globus Medical in the 2nd quarter worth $25,000. Root Financial Partners LLC acquired a new position in Globus Medical in the 3rd quarter worth $29,000. Heritage Family Offices LLP purchased a new position in Globus Medical in the 3rd quarter valued at about $31,000. Finally, Jacobi Capital Management LLC purchased a new position in Globus Medical in the 3rd quarter valued at about $40,000. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter EPS was $1.23, above the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, providing a potential shareholder-return boost. Q3 results and buyback announcement
• Positive Sentiment: Wells Fargo raised its price target to $100 and maintained an Overweight rating. Globus’s acquisition of Synaptive Medical also expands its cranial-neurosurgery offerings, though its financial impact remains to be seen. Synaptive acquisition
• Neutral Sentiment: Analyst actions were mixed: Needham lowered its target to $100 but kept a Buy rating, while Director Ann Rhoads sold 5,000 shares. The sale alone does not establish a change in the company’s outlook. Insider sale report
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million estimate and fell 0.7% year over year. 2026 revenue guidance of $3.1 billion is below the $3.2 billion consensus, while EPS guidance of $4.95–$5.05 is roughly in line with expectations. The company cited spine-launch delays and weak Nevro sales, and BMO downgraded GMED to Market Perform while cutting its target to $78. Earnings-call outlook and guidance

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.